Rallybio Drops Maternal Disorder Drug Following Phase 2 Failure
US-based biotechnology company Rallybio is discontinuing its RLYB212 program for preventing the development of fetal and neonatal alloimmune thrombocytopenia (FNAIT) due to unsatisfactory outcomes from...
View ArticleTrump’s Proposed Pharmaceutical Tariffs May Potentially Drive Up Prices and...
The U.S. may soon impose significant tariffs on pharmaceutical imports, according to President Donald Trump. At a recent National Republican Congressional Committee event, Trump said the initiative is...
View ArticleLife Sciences Voice Top Five Newsletter
Welcome to this week’s edition of the Life Sciences Voice Top Five Newsletter, your go-to source for the latest breakthroughs in the life sciences industry! This time, we’re taking a look at the...
View ArticleVanda Challenges FDA Over Limits on Off-Label Drug Communication
Vanda Pharmaceuticals is pushing back against the U.S. Food and Drug Administration (FDA), accusing the agency of stifling the dissemination of important medical information. The biotech company filed...
View ArticlePfizer Decides Against Pursuing Lead Obesity Asset Amid Liver Safety Concerns
Pfizer said that it had discovered a possible instance of medication-induced liver impairment and, as a result, would no longer be investing in the manufacturing of its oral GLP-1 medicine danuglipron....
View ArticleJ&J MedTech presents the first Ottava surgical robot clinical cases
Johnson & Johnson MedTech successfully conducted the initial clinical use of Ottava surgical robot through a minimally invasive gastric bypass procedure in Texas. The system received FDA approval...
View ArticleThe late-stage research of Bristol Myers’ heart disease medication falls...
Bristol Myers Squibb disclosed that its drug stavartanate did not successfully improve functional capacity or symptom intensities in heart disease patients, thus failing to reach the primary study...
View ArticleMerck Signs $493M Agreement to Use Cyprumed’s Oral Peptide Platform
Merck & Co. is taking a significant step toward transforming its peptide therapies into convenient oral tablets through a licensing agreement worth up to $493 million with Cyprumed, an...
View ArticleSanofi Deepens Autoimmune Push with $1.8B AI Biotech Deal
Sanofi’s ambition to become a dominant force in immunology continues to take shape, as the French pharmaceutical giant signs a deal worth up to $1.8 billion with U.S.-based biotech Earendil Labs. The...
View ArticleLilly’s Orforglipron Demonstrates Semaglutide-Like Efficacy in Phase 3 Type 2...
Eli Lilly’s oral GLP-1 receptor agonist orforglipron has met its primary efficacy endpoint in a Phase 3 trial, showing reductions in A1C and body weight on par with injectable semaglutide (Ozempic),...
View ArticleGSK’s Blenrep Returns with U.K. Approval for Multiple Myeloma Combination...
GSK has received regulatory approval in the United Kingdom for two new combination therapies featuring its antibody-drug conjugate (ADC) Blenrep, marking a significant step in the drug’s return to the...
View ArticleLife Sciences Voice Top Five Newsletter
Welcome to this week’s edition of the Life Sciences Voice Top Five Newsletter, your go-to source for the latest breakthroughs in the life sciences industry! This time, we’re taking a look at how liver...
View ArticleChinese CRO GemPharmatech Expands in San Diego as FDA Reevaluates Animal...
The Chinese contract research organization (CRO) GemPharmatech continues to increase its U.S. facilities by building a new center in San Diego which strengthens its market reach within the region. The...
View ArticleClick Therapeutics Gains FDA Clearance for First Prescription Digital...
Click Therapeutics has secured a notable regulatory milestone with the U.S. Food and Drug Administration granting authorization for CT-132, the agency’s first prescription digital therapeutic...
View ArticleVelaVigo Bio Strikes Second Major Licensing Agreement, Transfers Bispecific...
In a continued series of strategic moves, VelaVigo Bio, a biotechnology firm based in Shanghai, has finalized its second significant transaction within a six-month span. The latest agreement involves...
View ArticleBiolinq Secures $100 Million to Advance Glucose Biosensor and Expand...
Biolinq has announced the successful closure of a $100 million venture capital investment round aimed at finalizing the development of its wearable glucose biosensor. According to the company, the...
View ArticleRoche offers $50 billion to US pharma production in response to the tariff...
Roche, the drugmaker giant, announced its interest in investing $50 billion over five years in new and existing facilities across multiple states to expand U.S. drug production. Roche announced this...
View ArticleLife Sciences Voice Top Five Newsletter
Welcome to this week’s edition of the Life Sciences Voice Top Five Newsletter, your go-to source for the latest breakthroughs in the life sciences industry! This time, we’re taking a look at Roche’s...
View ArticleMedtronic Highlights Improved Results with Affera PFA Technology
Medtronic has announced encouraging clinical outcomes from two studies evaluating its pulsed field ablation (PFA) technologies. These studies focused on the Affera family of solutions, including the...
View ArticlePfizer’s PD-1 Inhibitor Shows Mixed Results in Bladder Cancer Trial
Pfizer has announced detailed results from its Phase 3 trial evaluating sasanlimab, a subcutaneous PD-1 inhibitor, in combination with Bacillus Calmette-Guérin (BCG) as a first-line treatment for...
View Article